Suppr超能文献

肝细胞生长因子、白细胞介素-1α和白细胞介素-27是新冠病毒肺炎患者早期严重程度分层的有力生物标志物。

HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients.

作者信息

Tamayo-Velasco Álvaro, Martínez-Paz Pedro, Peñarrubia-Ponce María Jesús, de la Fuente Ignacio, Pérez-González Sonia, Fernández Itziar, Dueñas Carlos, Gómez-Sánchez Esther, Lorenzo-López Mario, Gómez-Pesquera Estefanía, Heredia-Rodríguez María, Carnicero-Frutos Irene, Muñoz-Moreno María Fe, Bernardo David, Álvarez Francisco Javier, Tamayo Eduardo, Gonzalo-Benito Hugo

机构信息

Department of Hematology, University Clinical Hospital, 47003 Valladolid, Spain.

Department of Surgery, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain.

出版信息

J Clin Med. 2021 May 8;10(9):2017. doi: 10.3390/jcm10092017.

Abstract

Pneumonia is the leading cause of hospital admission and mortality in coronavirus disease 2019 (COVID-19). We aimed to identify the cytokines responsible for lung damage and mortality. We prospectively recruited 108 COVID-19 patients between March and April 2020 and divided them into four groups according to the severity of respiratory symptoms. Twenty-eight healthy volunteers were used for normalization of the results. Multiple cytokines showed statistically significant differences between mild and critical patients. High HGF levels were associated with the critical group (OR = 3.51; < 0.001; 95%CI = 1.95-6.33). Moreover, high IL-1α (OR = 1.36; = 0.01; 95%CI = 1.07-1.73) and low IL-27 (OR = 0.58; < 0.005; 95%CI = 0.39-0.85) greatly increased the risk of ending up in the severe group. This model was especially sensitive in order to predict critical status (AUC = 0.794; specificity = 69.74%; sensitivity = 81.25%). Furthermore, high levels of HGF and IL-1α showed significant results in the survival analysis ( = 0.033 and = 0.011, respectively). HGF, IL-1α, and IL 27 at hospital admission were strongly associated with severe/critical COVID-19 patients and therefore are excellent predictors of bad prognosis. HGF and IL-1α were also mortality biomarkers.

摘要

肺炎是2019冠状病毒病(COVID-19)患者住院和死亡的主要原因。我们旨在确定导致肺损伤和死亡的细胞因子。2020年3月至4月,我们前瞻性招募了108例COVID-19患者,并根据呼吸道症状的严重程度将他们分为四组。28名健康志愿者用于结果的标准化。轻度和重症患者之间多种细胞因子存在统计学显著差异。高HGF水平与重症组相关(OR = 3.51;<0.001;95%CI = 1.95 - 6.33)。此外,高IL-1α(OR = 1.36;= 0.01;95%CI = 1.07 - 1.73)和低IL-27(OR = 0.58;<0.005;95%CI = 0.39 - 0.85)大大增加了最终进入重症组的风险。该模型在预测重症状态方面特别敏感(AUC = 0.794;特异性 = 69.74%;敏感性 = 81.25%)。此外,高HGF和IL-1α水平在生存分析中显示出显著结果(分别为 = 0.033和 = 0.011)。入院时的HGF、IL-1α和IL-27与重症/危重症COVID-19患者密切相关,因此是不良预后的优秀预测指标。HGF和IL-1α也是死亡生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb70/8125923/c1ea0bc6d9fd/jcm-10-02017-g001.jpg

相似文献

2
Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129.
4
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208. doi: 10.3760/cma.j.issn.1001-0939.2020.03.013.
5
[Value of interleukin-6 and CD4 T-lymphocytopenia in assessing the severity and prognosis of coronavirus disease 2019].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Oct;32(10):1165-1170. doi: 10.3760/cma.j.cn121430-20200521-00395.
6
[Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):559-563. doi: 10.3760/cma.j.cn121430-20200414-00518.
7
Characterization of the Inflammatory Response to Severe COVID-19 Illness.
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821. doi: 10.1164/rccm.202005-1583OC.
9
IL-6-based mortality risk model for hospitalized patients with COVID-19.
J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9. doi: 10.1016/j.jaci.2020.07.009. Epub 2020 Jul 22.
10
[Analysis of the changes of inflammatory cytokine levels in patients with critical coronavirus disease 2019 undergoing invasive mechanical ventilation].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Sep;32(9):1051-1055. doi: 10.3760/cma.j.cn121430-20200414-00519.

引用本文的文献

5
Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsis.
J Infect. 2024 Dec;89(6):106300. doi: 10.1016/j.jinf.2024.106300. Epub 2024 Sep 30.
6
IL-27 expression regulation and its effects on adaptive immunity against viruses.
Front Immunol. 2024 Jun 20;15:1395921. doi: 10.3389/fimmu.2024.1395921. eCollection 2024.
9
Severity of oxidative stress as a hallmark in COVID-19 patients.
Eur J Med Res. 2023 Dec 4;28(1):558. doi: 10.1186/s40001-023-01401-2.

本文引用的文献

1
Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome.
Cell Rep Med. 2021 May 18;2(5):100269. doi: 10.1016/j.xcrm.2021.100269. Epub 2021 Apr 19.
2
Interleukin-6: obstacles to targeting a complex cytokine in critical illness.
Lancet Respir Med. 2021 Jun;9(6):643-654. doi: 10.1016/S2213-2600(21)00103-X. Epub 2021 Apr 16.
3
COVID-19 and the human innate immune system.
Cell. 2021 Apr 1;184(7):1671-1692. doi: 10.1016/j.cell.2021.02.029. Epub 2021 Feb 16.
4
IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts.
J Allergy Clin Immunol. 2021 May;147(5):1652-1661.e1. doi: 10.1016/j.jaci.2021.02.021. Epub 2021 Mar 1.
5
A neutrophil activation signature predicts critical illness and mortality in COVID-19.
Blood Adv. 2021 Mar 9;5(5):1164-1177. doi: 10.1182/bloodadvances.2020003568.
6
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
7
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
8
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
J Allergy Clin Immunol. 2021 Jan;147(1):72-80.e8. doi: 10.1016/j.jaci.2020.09.018. Epub 2020 Sep 30.
9
Longitudinal analyses reveal immunological misfiring in severe COVID-19.
Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y. Epub 2020 Jul 27.
10
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验